下载掌阅APP，畅读海量书库
立即打开
［1］ZHANG L, WANG H, LONG J, et al. China kidney disease network (CK-NET) 2014 annual data report [J]. Am J Kidney Dis, 2017, 69 (6S2): A4.
［2］LI J, CUI Z, LONG J, et al. Primary glomerular nephropathy among hospitalized patients in a national database in China [J]. Nephrol Dial Transplant, 2018, 33 (12): 2173-2181.
［3］YANG Y, ZHANG Z, ZHUO L, et al. The spectrum of biopsy-proven glomerular disease in china: a systematic review [J]. Chin Med J (Engl), 2018, 131 (6): 731-735.
［4］SCHENA F P, NISTOR I. Epidemiology of IgA nephropathy: a global perspective [J]. Semin Nephrol, 2018,38 (5): 435-442.
［5］MCQUARRIE E P, MACKINNON B, MCNEICE V, et al. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation [J]. Kidney Int, 2014, 85 (1): 198-203.
［6］SIM J J, BATECH M, HEVER A, et al. Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population [J]. Am J Kidney Dis, 2016, 68 (4): 533-544.
［7］O′SHAUGHNESSY M M, HOGAN S L, POULTON C J, et al. Temporal and demographic trends in glomerular disease epidemiology in the southeastern united states. 1986-2015 [J]. Clin J Am Soc Nephrol,2017, 12 (4): 614-623.
［8］TRIMARCHI H, BARRATT J, CATTRAN DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group [J]. Kidney Int, 2017, 91 (5): 1014-1021.
［9］MAGISTRONI R, D′AGATI V D, APPEL G B, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy [J]. Kidney Int, 2015, 88 (5): 974-989.
［10］ZHAI Y L, ZHU L, SHI S F, et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy [J]. Medicine, 2016, 95 (11): e3099.
［11］ROSENBLAD T, REBETZ J, JOHANSSON M, et al. Eculizumab treatment for rescue of renal function in IgA nephropathy [J]. Pediatr Nephrol, 2014, 29 (11): 2225-2228.
［12］RIGN T, PEDERSEN B B, SALKUS G, et al. Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum？[J]. Clin Kidney J, 2015, 8 (5): 489-491.
［13］ESPINOSA M, ORTEGA R, SANCHEZ M, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2014, 9 (5): 897-904.
［14］FARIA B, HENRIQUES C, MATOS A C, et al. Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig) A nephropathy progression [J]. Clin Exp Immunol, 2015, 179 (2): 354-361.
［15］MAENG Y I, KIM M K, PARK J B, et al. Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria [J]. Int J Clin Exp Pathol, 2013, 6 (5): 904-910.
［16］QI Y Y, ZHOU X J, CHENG F J, et al. DEFA gene variants associated with IgA nephropathy in a Chinese population [J]. Genes Immun, 2015, 16 (3): 231-237.
［17］KIRYLUK K, LI Y, SCOLARI F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens [J]. Nat Genet, 2014, 46 (11): 1187-1196.
［18］XU R, FENG S, LI Z, et al. Polymorphism of DEFA in Chinese Han population with IgA nephropathy [J]. Hum Genet, 2014, 133 (10): 1299-1309.
［19］HAAS M, VERHAVE J C, LIU Z H, et al. A Multicenter study of the predictive value of crescents in IgA nephropathy [J]. J Am Soc Nephrol, 2017, 28 (2): 691-701.
［20］RAUEN T, EITNER F, FITZNER C, et al. Intensive Supportive care plus immunosuppression in IgA nephropathy [J]. N Engl J Med, 2015, 373 (23): 2225-2236.
［21］LV J, ZHANG H, WONG M G, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial [J]. JAMA, 2017, 318 (5): 432-442.
［22］FELLSTROM B C, BARRATT J, COOK H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial [J]. Lancet, 2017, 389 (10084): 2117-2127.